Scarica l'app Stockscreener
2.98
3.11%
0.09
Dopo l'orario di chiusura:
3.00
0.02
+0.67%
Protara Therapeutics Inc Borsa (TARA) Ultime notizie
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Why EchoStar Stock Is Soaring Higher Today - The Globe and Mail
Two Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025 (NASDAQ:TARA) - Seeking Alpha
SoundHound AI (SOUN): This High-Potential Growth Stock Could Be Your Smartest Bet under $10 - The Globe and Mail
Where Will Uber Stock Be in 5 Years? - The Globe and Mail
Company News for Jun 13, 2025 - The Globe and Mail
Protara Therapeutics Holds Annual Stockholders Meeting - TipRanks
These 3 ‘Bro Billionaire’ Stocks Are Wildly Outperforming in Trump’s Market - The Globe and Mail
Kantar appoints Jeff Greenspoon as CEO, Americas - The Globe and Mail
Cantor Fitzgerald Forecasts TARA FY2026 Earnings - Defense World
Squarepoint Ops LLC Makes New $110,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Steven Hudson buying at ECN Capital (ECN) - The Globe and Mail
Protara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DE - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of “Buy” by Analysts - Defense World
Why Shares of Tesla Are Sinking Today - The Globe and Mail
Is Costco a Buy Now? - The Globe and Mail
Millennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics names new Chief Commercial Officer By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) Appoints New Chief Commercial Officer | TARA Stock News - GuruFocus
Protara Therapeutics names new Chief Commercial Officer - Investing.com
Protara Therapeutics Names William Conkling as Chief Commercial Officer - MarketScreener
Protara Therapeutics Announces Appointment Of William Conkling As Chief Commercial Officer - marketscreener.com
Protara Therapeutics Announces Appointment of William Conkling a - GuruFocus
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer - GlobeNewswire
Cancer Drug Veteran Behind Trodelvy Launch Joins Protara as Commercial Chief to Lead Market Strategy - Stock Titan
The Next Stock I'm Buying? - The Globe and Mail
Transcript : Protara Therapeutics, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 01 - marketscreener.com
Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation - Nasdaq
Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating - GuruFocus
Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating | TARA Stock News - GuruFocus
Protara Therapeutics (TARA) Receives Buy Rating with $21 Price T - GuruFocus
Jones Initiates Protara Therapeutics at Buy With $21 Price Target - marketscreener.com
Richard Levy Spends US$64k On Protara Therapeutics Stock - Yahoo Finance
BNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Dimensional Fund Advisors LP Makes New $111,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Richard Levy Bought 65% More Shares In Protara Therapeutics - simplywall.st
Insider Buying: Richard Levy Acquires 20,000 Shares of Protara T - GuruFocus
With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing - Yahoo Finance
Protara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Buy” from Brokerages - Defense World
Protara Therapeutics Reports Q1 2025 Financial Results - TipRanks
Protara Therapeutics: Q1 Earnings Snapshot - New Haven Register
Barclays PLC Takes $492,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile - TipRanks
Protara (TARA) Strengthens Leadership with Key Appointments | TA - GuruFocus
Protara Therapeutics (TARA) Sees Positive Results in TARA-002 Trial | TARA Stock News - GuruFocus
Protara (TARA) Strengthens Leadership with Key Appointments | TARA Stock News - GuruFocus
1.02%
1.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):